Form 4: Tarsus Pharmaceuticals' Chief Medical Officer Acquires Stock Options and Restricted Stock Units

Elizabeth Yeu Lin, Chief Medical Officer of Tarsus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Summary

• Elizabeth Yeu Lin, the Chief Medical Officer of Tarsus Pharmaceuticals, filed a Form 4 on March 7, 2025, reporting changes in beneficial ownership.
• On March 5, 2025, Lin acquired 15,314 stock options with an exercise price of $44.54.
• These options vest 25% on March 5, 2026, and then 1/48th monthly for the following three years, contingent upon continuous service.
• Lin also acquired 10,045 restricted stock units (RSUs) on the same date.
• These RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, also subject to continuous service.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, but reflects standard compensation practices.

Positives

• The acquisition of stock options and RSUs aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company's success.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules suggest an expectation of continued employment and contribution from the Chief Medical Officer.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates compensation and alignment of interests.

Stakeholder Impact

• The acquisition of stock options and RSUs by the Chief Medical Officer aligns her interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates